Jimin trusted new crown and antibody initiated Phase 1 clinical

Today (January 20), Jimin Trust Group announced that its new coronavirus-innate antibody, JMB2002, has launched Phase 1 clinical trials at Shulan (Hangzhou) Hospital.
JMB2002 is an all-human-specific neutral antibody developed by Jimin Trust Group Shanghai Research Institute, which is intended to be used to prevent and treat new coronavirus infections.
, the development of antibodies is also an important direction in the development of antibodies to combat new coronavirus infections.
mentions the middle antibody, and perhaps the most familiar is its meso-function.
neutral antibodies by combining with specific antigens on the surface of the virus to prevent them from combining with the expression of the subject on the cell and entering the cell.
this function prevents viruses from infecting cells that have not yet been infected.
, the antibody can be used for the prevention and treatment of new coronary infections.
One of the key steps for new coronavirus to infect human cells is the binding domain (RBD) of the virus surface prickline protein (S protein) S1 sub-base to the angiotensin-converting enzyme 2 (angiotensin II converting enzyme 2, ACE2) protein on the surface of the human cell, triggering the internal swallowing of human cells to swallow the virus into the cells.
, several currently being developed in the world are targeting the RBD region of the new coronavirus S protein.
this is a key protein domain in which S proteins bind to ACE2 binds to ace2 in cells, preventing new coronavirus from infecting human cells by blocking their interactions.
According to Jemin's trusted press release, the company is developing a medium antibody, JMB2002, that precisely occupies the key tables of the S1 sub-base binding domain (RBD) binding interface of the virus S protein and ACE2 binding interface, and has a stronger binding and blocking utility.
preclinical study, JMB2002 also found that JMB2002 was effective in infecting African green monkey kidney cells with live viruses.
, as an all-human antibody, predicts that its immunogenicity will be low, and that its Fc mutation is expected to reduce antibody dependence (ADE) effects and the risk of cytokine storms.
it is understood that JMB2002 is derived from a library of natural antibodies of 10 billion healthy human B-cells, obtained through precise antibody screening technology that seamlessly interfaces with yeast display, and that in the key steps of streaming high-volume screening, researchers creatively added new crowns The viral surface hedgehog glycoprotein and its human host's binder protein, simulated and antibody binding to the virus to block its binding to the human host of the process, so that in the 10 billion-level natural antibody library quickly screening to the optimal molecule, the process took only 19 days.
, the team conducted a series of preclinical studies.
in animal experiments, researchers studied the metabolic laws, safety and effectiveness of JMB2002 in primates.
study found that in the model of rhesus monkey virus infection in pharmacological research, the prevention group animals were able to effectively defend against the infection of the virus to the body after early drug treatment, and the treatment group animals after the infection of the virus, the lung tissue site did not detect the viral load, preventing the damage to the lungs of the virus infection, showing a more ideal therapeutic effect.
in the cancer-eating monkey model studied in toxicology, after four consecutive administrations, no drug-related toxic side effects were observed in each dose group, and the safety performance was excellent.
study also found that JMB2002 can accurately occupy the virus S protein S1 sub-base on the bind domain (RBD) and ACE2 binding interface of the key table, and has a strong binding, blocking effect.
early studies, JMB2002 was found to be effective in infecting African green monkey kidney cells with live viruses.
noteworthy is that JMB2002 showed good binding and blocking activity against different mutant virus pyrethrins.
JMB2002 is the first biological drug to enter the clinical stage of Jimin Trust.
that the follow-up clinical study of this medium antibody will be carried out smoothly and can benefit human health as soon as possible.
follow the public number of WeChat